AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20592230 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual lens wear
Number of subjects: 48
Study 20592230 — intervention group
Group type: EXPERIMENTAL
Intervention: PHMB-preserved solution
Number of subjects: 48
Study 20592230 — intervention group
Group type: COMPARATOR
Intervention: Polyquad/Aldox system
Number of subjects: 48
Study 16644196 — intervention group
Group type: EXPERIMENTAL
Intervention: Hochu-ekki-to (HET) 7.5 g/day for two weeks
Number of subjects: 32
Study 16644196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (indistinguishable) 7.5 g/day for two weeks
Number of subjects: 32
Study 16644196 — intervention group
Group type: EXPERIMENTAL
Intervention: HET and Control (Placebo)
Number of subjects: 32
Study 16249679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal‐epidural technique with 27‐gauge Whitacre needle dural puncture without subarachnoid drug administration
Number of subjects: 251
Study 16249679 — intervention group
Group type: COMPARATOR
Intervention: Traditional epidural technique
Number of subjects: 251
Study 11867391 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 30
Study 11867391 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 30
Study 10667430 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months combined androgen blockade therapy (n = 18)
Number of subjects: 40
Study 10667430 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months combined androgen blockade therapy (n = 22)
Number of subjects: 40
Study 8675576 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 24
Study 8675576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1858189 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg administered as an enema
Number of subjects: 23
Study 1858189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6136287 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 198
Study 6136287 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallamine
Number of subjects: 198
Study 6136287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 198
Study 6136287 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 198
Study 6136287 — intervention group
Group type: COMPARATOR
Intervention: Inert medication (Control)
Number of subjects: 198
Study 31264430 — intervention group
Group type: EXPERIMENTAL
Intervention: 70-gene MammaPrint assay
Number of subjects: 0
Study 31264430 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 28346843 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal milk odor during venipuncture
Number of subjects: 33
Study 28346843 — intervention group
Group type: COMPARATOR
Intervention: Control group (odorless diffuser)
Number of subjects: 33
Study 27986742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide for 6 weeks
Number of subjects: 220
Study 27986742 — intervention group
Group type: COMPARATOR
Intervention: Control treatment for 6 weeks
Number of subjects: 220
Study 27986742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 220
Study 27986742 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 220
Study 23755902 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial dentures (RPDs) constructed from Co‐Cr‐Mo alloy
Number of subjects: 28
Study 23755902 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial dentures (RPDs) constructed from Ti6Al4V alloy
Number of subjects: 28
Study 23755902 — intervention group
Group type: COMPARATOR
Intervention: Buffered saline solution (in vitro)
Number of subjects: 28
Study 23755902 — intervention group
Group type: COMPARATOR
Intervention: Saliva samples (in vivo)
Number of subjects: 28
Study 22370326 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin alone
Number of subjects: 205
Study 22370326 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin with dexrazoxane
Number of subjects: 205
Study 19574864 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) of 2 segments at T10 and L1 vertebrae levels
Number of subjects: 50
Study 19574864 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral block (PVB) through 4 segments at T10, T11, T12, and L1
Number of subjects: 50
Study 19574864 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil consumption
Number of subjects: 50
Study 19574864 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery start time
Number of subjects: 50
Study 19574864 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative visual analog scale scores
Number of subjects: 50
Study 19574864 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 50
Study 17878242 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin monotherapy (100 mg daily)
Number of subjects: 238
Study 17878242 — intervention group
Group type: COMPARATOR
Intervention: Active comparator group
Number of subjects: 238
Study 14763497 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzer reprocessing
Number of subjects: 1285
Study 14763497 — intervention group
Group type: EXPERIMENTAL
Intervention: Qb above 250 ml/min
Number of subjects: 1285
Study 14763497 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Qd from 500 to 800 ml/min
Number of subjects: 1285
Study 14763497 — intervention group
Group type: EXPERIMENTAL
Intervention: New algorithm for estimating Qb and K0A
Number of subjects: 1285
Study 14763497 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 1285
Study 11117451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead stimulus change (acoustic vs. visual)
Number of subjects: 96
Study 11117451 — intervention group
Group type: COMPARATOR
Intervention: No change condition
Number of subjects: 96
Study 9327699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 20
Study 9327699 — intervention group
Group type: COMPARATOR
Intervention: Nicorandil
Number of subjects: 20
Study 8404176 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 0.125 mg
Number of subjects: 10
Study 8404176 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 1.5 mg
Number of subjects: 10
Study 8404176 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) 10 cm H2O
Number of subjects: 10
Study 8404176 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) 15 cm H2O
Number of subjects: 10
Study 8404176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8404176 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP)
Number of subjects: 10
Study 3492486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg twice daily for ten days)
Number of subjects: 65
Study 3492486 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (160 mg trimethoprim and 800 mg sulphamethoxazole twice daily for ten days)
Number of subjects: 65
Study 3492486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 65
Study 3492486 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 65
Study 3398018 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instruction videotape
Number of subjects: 60
Study 3398018 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing and critiquing a videotape of their interview
Number of subjects: 60
Study 3398018 — intervention group
Group type: EXPERIMENTAL
Intervention: Both self-instruction videotape and critiquing a videotape of their interview
Number of subjects: 60
Study 3398018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational interventions)
Number of subjects: 60
Study 31734992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous portal vein punctures combined with bi-directional angiography
Number of subjects: 15
Study 31734992 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods for TIPS
Number of subjects: 15
Study 28793880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentraxin-3 (PTX-3)
Number of subjects: 213
Study 26093156 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal imaging marker (randomized denoising autoencoder marker, rDAm)
Number of subjects: 0
Study 23123868 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive passive movement (RPM) intervention, 3 times a week for 8 weeks, using a continuous passive motion device at a velocity of 15°/s for 20 min
Number of subjects: 18
Study 23123868 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 18
Study 21540741 — intervention group
Group type: EXPERIMENTAL
Intervention: GW842166 800 mg
Number of subjects: 0
Study 21540741 — intervention group
Group type: EXPERIMENTAL
Intervention: GW842166 100 mg
Number of subjects: 0
Study 21540741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 21540741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18510961 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (321 mg flavanols per dose)
Number of subjects: 41
Study 18510961 — intervention group
Group type: COMPARATOR
Intervention: Nutrient-matched control (25 mg flavanols per dose)
Number of subjects: 41
Study 18510961 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (single acute dose)
Number of subjects: 41
Study 16556691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 171
Study 16556691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 12777271 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 25 mg
Number of subjects: 554
Study 12777271 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 50 mg
Number of subjects: 554
Study 12777271 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 75 mg
Number of subjects: 554
Study 12777271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 12777271 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (all doses)
Number of subjects: 554
Study 10689248 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 17
Study 10689248 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with FMR
Number of subjects: 17
Study 9315986 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg/day + Fluoxetine 20 mg/day
Number of subjects: 27
Study 9315986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9315986 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 7.5 mg/day
Number of subjects: 27
Study 8447613 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine 0.25 mg with adrenaline 200 micrograms (group MA)
Number of subjects: 75
Study 8447613 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine 0.25 mg without adrenaline (group M)
Number of subjects: 75
Study 8447613 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 75
Study 3948442 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 10
Study 3948442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30658914 — intervention group
Group type: EXPERIMENTAL
Intervention: ARD-3150 (3 mL liposome encapsulated ciprofloxacin 135 mg and 3 mL free ciprofloxacin 54 mg)
Number of subjects: 278
Study 30658914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 mL placebo: 3 mL dilute empty liposomes mixed with 3 mL of saline)
Number of subjects: 278
Study 30658914 — intervention group
Group type: EXPERIMENTAL
Intervention: ARD-3150
Number of subjects: 278
Study 30658914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 28393819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented posts (dual: Ambar/Allcem)
Number of subjects: 72
Study 28393819 — intervention group
Group type: EXPERIMENTAL
Intervention: Relined posts (dual: Ambar/Allcem)
Number of subjects: 72
Study 28393819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented posts (chemical: Fusion Duralink/Cement Post)
Number of subjects: 72
Study 28393819 — intervention group
Group type: EXPERIMENTAL
Intervention: Relined posts (chemical: Fusion Duralink/Cement Post)
Number of subjects: 72
Study 26241250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracesarean delivery
Number of subjects: 112
Study 26241250 — intervention group
Group type: COMPARATOR
Intervention: Interval IUD placement
Number of subjects: 112
Study 24215228 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention (smoking cessation brochure, list of smoking cessation resources, and patient navigation)
Number of subjects: 47
Study 24215228 — intervention group
Group type: COMPARATOR
Intervention: Control group (smoking cessation brochure and a list of smoking cessation resources)
Number of subjects: 47
Study 21189431 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 10 mg daily for 2 months
Number of subjects: 95
Study 21189431 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin, 40 mg daily for 2 months
Number of subjects: 95
Study 21189431 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg daily for 2 months
Number of subjects: 95
Study 21189431 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 95
Study 21189431 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 95
Study 21189431 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 95
Study 21189431 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, Simvastatin, Lovastatin
Number of subjects: 95
Study 18776057 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and leucovorin (LV) plus bevacizumab (BV)
Number of subjects: 249
Study 18776057 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) and leucovorin (LV)
Number of subjects: 249
Study 18776057 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan, 5-FU, and leucovorin (LV) plus bevacizumab (BV)
Number of subjects: 249
Study 18776057 — intervention group
Group type: COMPARATOR
Intervention: irinotecan, 5-FU, and leucovorin (LV)
Number of subjects: 249
Study 17161072 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention in 19 hospitals
Number of subjects: 6726
Study 17161072 — intervention group
Group type: COMPARATOR
Intervention: Control group in 19 hospitals
Number of subjects: 6726
Study 14961173 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily application of Dovobet (calcipotriol 50 micrograms/gram and betamethasone dipropionate 0.5 milligrams/gram)
Number of subjects: 5500
Study 14961173 — intervention group
Group type: COMPARATOR
Intervention: Twice daily application of Dovobet
Number of subjects: 5500
Study 14961173 — intervention group
Group type: COMPARATOR
Intervention: Individual components used alone (calcipotriol or betamethasone dipropionate)
Number of subjects: 5500
Study 10660736 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU), 300 mg/day
Number of subjects: 166
Study 10660736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPA), 150 mg/day
Number of subjects: 166
Study 10660736 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU + CPA
Number of subjects: 166
Study 10660736 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 166
Study 9070555 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training only
Number of subjects: 55
Study 9070555 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification only
Number of subjects: 55
Study 9070555 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training plus dietary modification
Number of subjects: 55
Study 8451405 — intervention group
Group type: EXPERIMENTAL
Intervention: Body temperature contrast medium (n = 117)
Number of subjects: 250
Study 8451405 — intervention group
Group type: COMPARATOR
Intervention: Room temperature contrast medium (n = 133)
Number of subjects: 250
Study 3085464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (60 to 90 mg/day)
Number of subjects: 21
Study 3085464 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg/day)
Number of subjects: 21
Study 3085464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31569173 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise program plus neural gliding
Number of subjects: 26
Study 31569173 — intervention group
Group type: COMPARATOR
Intervention: Multimodal exercise program only
Number of subjects: 26
Study 30475961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet with higher genetic risk score (GRS) for vitamin D
Number of subjects: 424
Study 30475961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet with lower genetic risk score (GRS) for vitamin D
Number of subjects: 424
Study 30475961 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 424
Study 30475961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 424
Study 29262474 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical velocimetry (EV)
Number of subjects: 60
Study 29262474 — intervention group
Group type: COMPARATOR
Intervention: Traditional central venous pressure (CVP)
Number of subjects: 60
Study 25783672 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerted action to reduce cesarean section rates
Number of subjects: 0
Study 23468176 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept at 0.4 mg/kg per week for the first year, then 0.4 mg/kg per month for the second year
Number of subjects: 31
Study 21112538 — intervention group
Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated 2% ropivacaine gel (RL2)
Number of subjects: 40
Study 21112538 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% benzocaine gel (B20)
Number of subjects: 40
Study 21112538 — intervention group
Group type: COMPARATOR
Intervention: placebo gel (P)
Number of subjects: 40
Study 21112538 — intervention group
Group type: COMPARATOR
Intervention: liposomal placebo gel (LP)
Number of subjects: 40
Study 18480205 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg of rFVIIa per kilogram
Number of subjects: 841
Study 18480205 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg of rFVIIa per kilogram
Number of subjects: 841
Study 18480205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 841
Study 18480205 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (placebo, 20 microg rFVIIa, 80 microg rFVIIa)
Number of subjects: 841
Study 16641282 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Number of subjects: 64
Study 14765752 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from the contact point to the bone crest of 5 mm or less
Number of subjects: 45
Study 14765752 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from the contact point to the bone crest of 6 mm
Number of subjects: 45
Study 14765752 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from the contact point to the bone crest of 7 mm or greater
Number of subjects: 45
Study 11044164 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 27
Study 11044164 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (nil-by-mouth regimen)
Number of subjects: 27
Study 8652355 — intervention group
Group type: EXPERIMENTAL
Intervention: MLD children
Number of subjects: 40
Study 8652355 — intervention group
Group type: COMPARATOR
Intervention: Typical children
Number of subjects: 40
Study 1859906 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen therapy
Number of subjects: 0
Study 1859906 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-relapse tamoxifen therapy
Number of subjects: 0
Study 1859906 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF adjuvant therapy
Number of subjects: 0
Study 1859906 — intervention group
Group type: COMPARATOR
Intervention: 2-year course of tamoxifen
Number of subjects: 0
Study 6125172 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (3 x 40 mg)
Number of subjects: 10
Study 6125172 — intervention group
Group type: COMPARATOR
Intervention: Pindolol (3 x 5 mg)
Number of subjects: 10
Study 6125172 — intervention group
Group type: COMPARATOR
Intervention: Both beta‐adrenoceptor blockers
Number of subjects: 10
Study 31827767 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative therapy
Number of subjects: 238
Study 31827767 — intervention group
Group type: COMPARATOR
Intervention: Non-manipulative therapy
Number of subjects: 238
Study 27657352 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively increasing task difficulty (PT)
Number of subjects: 0
Study 27657352 — intervention group
Group type: COMPARATOR
Intervention: No progression (NPT)
Number of subjects: 0
Study 26715818 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS program (n = 30)
Number of subjects: 61
Study 26715818 — intervention group
Group type: COMPARATOR
Intervention: Conventional control group (n = 31)
Number of subjects: 61
Study 23867982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TMX) 20 mg orally for 3 months
Number of subjects: 21
Study 23867982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20727096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation (CRYO)
Number of subjects: 20
Study 20727096 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 20
Study 18695943 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 20479
Study 16967285 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic-floor exercises (24 training sessions over 3 months)
Number of subjects: 56
Study 16967285 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (16 sessions over 2 months)
Number of subjects: 56
Study 16967285 — intervention group
Group type: COMPARATOR
Intervention: Pelvic-floor exercises and biofeedback therapy
Number of subjects: 56
Study 15689088 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa HBV-IPV-Hib vaccine at 1 1/2, 3 and 5 months of age
Number of subjects: 150